Redefining  ||| S:0 E:11 ||| JJ
treatment  ||| S:11 E:21 ||| NN
success  ||| S:21 E:29 ||| NN
in  ||| S:29 E:32 ||| IN
type  ||| S:32 E:37 ||| NN
2  ||| S:37 E:39 ||| CD
diabetes  ||| S:39 E:48 ||| NN
mellitus ||| S:48 E:56 ||| NNS
:  ||| S:56 E:58 ||| :
Comprehensive  ||| S:58 E:72 ||| NNP
targeting  ||| S:72 E:82 ||| VBG
of  ||| S:82 E:85 ||| IN
core  ||| S:85 E:90 ||| JJ
defects  ||| S:90 E:98 ||| NNS
Despite  ||| S:98 E:106 ||| IN
advances  ||| S:106 E:115 ||| NNS
in  ||| S:115 E:118 ||| IN
diagnosis  ||| S:118 E:128 ||| NN
and  ||| S:128 E:132 ||| CC
treatment ||| S:132 E:141 ||| NN
,  ||| S:141 E:143 ||| ,
type  ||| S:143 E:148 ||| NN
2  ||| S:148 E:150 ||| CD
diabetes  ||| S:150 E:159 ||| NN
mellitus  ||| S:159 E:168 ||| NNS
( ||| S:168 E:169 ||| -LRB-
T2DM ||| S:169 E:173 ||| NNP
) ||| S:173 E:174 ||| -RRB-
,  ||| S:174 E:176 ||| ,
overweight ||| S:176 E:186 ||| FW
/ ||| S:186 E:187 ||| FW
obesity ||| S:187 E:194 ||| FW
,  ||| S:194 E:196 ||| ,
cardiovascular  ||| S:196 E:211 ||| JJ
disease ||| S:211 E:218 ||| NN
,  ||| S:218 E:220 ||| ,
and  ||| S:220 E:224 ||| CC
their  ||| S:224 E:230 ||| PRP$
sequelae  ||| S:230 E:239 ||| NNS
are  ||| S:239 E:243 ||| VBP
major  ||| S:243 E:249 ||| JJ
public  ||| S:249 E:256 ||| JJ
health  ||| S:256 E:263 ||| NN
burdens  ||| S:263 E:271 ||| NNS
worldwide ||| S:271 E:280 ||| VBD
.  ||| S:280 E:282 ||| .
The  ||| S:282 E:286 ||| DT
understanding  ||| S:286 E:300 ||| NN
of  ||| S:300 E:303 ||| IN
the  ||| S:303 E:307 ||| DT
pathophysiology  ||| S:307 E:323 ||| NN
of  ||| S:323 E:326 ||| IN
T2DM  ||| S:326 E:331 ||| NNP
has  ||| S:331 E:335 ||| VBZ
traditionally  ||| S:335 E:349 ||| RB
emphasized  ||| S:349 E:360 ||| VBD
decreased  ||| S:360 E:370 ||| VBN
insulin  ||| S:370 E:378 ||| NN
secretion  ||| S:378 E:388 ||| NNS
and  ||| S:388 E:392 ||| CC
increased  ||| S:392 E:402 ||| JJ
insulin  ||| S:402 E:410 ||| NN
resistance ||| S:410 E:420 ||| NN
,  ||| S:420 E:422 ||| ,
but  ||| S:422 E:426 ||| CC
evolving  ||| S:426 E:435 ||| VBG
concepts  ||| S:435 E:444 ||| NNS
now  ||| S:444 E:448 ||| RB
include  ||| S:448 E:456 ||| VB
the  ||| S:456 E:460 ||| DT
role  ||| S:460 E:465 ||| NN
of  ||| S:465 E:468 ||| IN
incretin  ||| S:468 E:477 ||| JJ
hormones  ||| S:477 E:486 ||| NNS
in  ||| S:486 E:489 ||| IN
disease  ||| S:489 E:497 ||| NN
progression ||| S:497 E:508 ||| NN
.  ||| S:508 E:510 ||| .
A  ||| S:510 E:512 ||| DT
comprehensive  ||| S:512 E:526 ||| JJ
approach  ||| S:526 E:535 ||| NN
to  ||| S:535 E:538 ||| TO
managing  ||| S:538 E:547 ||| VBG
patients  ||| S:547 E:556 ||| NNS
with  ||| S:556 E:561 ||| IN
T2DM  ||| S:561 E:566 ||| NNP
requires  ||| S:566 E:575 ||| VBZ
targeting  ||| S:575 E:585 ||| VBG
both  ||| S:585 E:590 ||| PDT
the  ||| S:590 E:594 ||| DT
fundamental  ||| S:594 E:606 ||| JJ
defects  ||| S:606 E:614 ||| NNS
of  ||| S:614 E:617 ||| IN
the  ||| S:617 E:621 ||| DT
disease  ||| S:621 E:629 ||| NN
and  ||| S:629 E:633 ||| CC
its  ||| S:633 E:637 ||| PRP$
comorbidities ||| S:637 E:650 ||| NN
,  ||| S:650 E:652 ||| ,
including  ||| S:652 E:662 ||| VBG
the  ||| S:662 E:666 ||| DT
sequelae  ||| S:666 E:675 ||| NN
of  ||| S:675 E:678 ||| IN
nonoptimal  ||| S:678 E:689 ||| JJ
control  ||| S:689 E:697 ||| NN
of  ||| S:697 E:700 ||| IN
blood  ||| S:700 E:706 ||| NN
glucose ||| S:706 E:713 ||| NN
,  ||| S:713 E:715 ||| ,
blood  ||| S:715 E:721 ||| NN
pressure ||| S:721 E:729 ||| NN
,  ||| S:729 E:731 ||| ,
body  ||| S:731 E:736 ||| NN
weight ||| S:736 E:742 ||| NN
,  ||| S:742 E:744 ||| ,
and  ||| S:744 E:748 ||| CC
lipids ||| S:748 E:754 ||| NN
.  ||| S:754 E:756 ||| .
Newer  ||| S:756 E:762 ||| JJR
antidiabetes  ||| S:762 E:775 ||| JJ
agents ||| S:775 E:781 ||| NNS
,  ||| S:781 E:783 ||| ,
such  ||| S:783 E:788 ||| JJ
as  ||| S:788 E:791 ||| IN
the  ||| S:791 E:795 ||| DT
glucagon-like  ||| S:795 E:809 ||| JJ
peptide-1  ||| S:809 E:819 ||| NNP
( ||| S:819 E:820 ||| -LRB-
GLP-1 ||| S:820 E:825 ||| NNP
)  ||| S:825 E:827 ||| -RRB-
receptor  ||| S:827 E:836 ||| NN
agonists  ||| S:836 E:845 ||| NNS
and  ||| S:845 E:849 ||| CC
the  ||| S:849 E:853 ||| DT
dipeptidyl  ||| S:853 E:864 ||| JJ
peptidase-4  ||| S:864 E:876 ||| NNP
( ||| S:876 E:877 ||| -LRB-
DPP-4 ||| S:877 E:882 ||| NNP
)  ||| S:882 E:884 ||| -RRB-
inhibitors ||| S:884 E:894 ||| NN
,  ||| S:894 E:896 ||| ,
address  ||| S:896 E:904 ||| VB
fundamental  ||| S:904 E:916 ||| JJ
defects  ||| S:916 E:924 ||| NNS
related  ||| S:924 E:932 ||| VBN
to  ||| S:932 E:935 ||| TO
glycemic  ||| S:935 E:944 ||| VB
control  ||| S:944 E:952 ||| NN
in  ||| S:952 E:955 ||| IN
T2DM  ||| S:955 E:960 ||| NNP
and  ||| S:960 E:964 ||| CC
may  ||| S:964 E:968 ||| MD
have  ||| S:968 E:973 ||| VB
potential  ||| S:973 E:983 ||| JJ
effects  ||| S:983 E:991 ||| NNS
on  ||| S:991 E:994 ||| IN
other  ||| S:994 E:1000 ||| JJ
markers  ||| S:1000 E:1008 ||| NN
of  ||| S:1008 E:1011 ||| IN
cardiovascular  ||| S:1011 E:1026 ||| JJ
risk ||| S:1026 E:1030 ||| NN
.  ||| S:1030 E:1032 ||| .
A  ||| S:1032 E:1034 ||| DT
redefinition  ||| S:1034 E:1047 ||| NN
of  ||| S:1047 E:1050 ||| IN
treatment  ||| S:1050 E:1060 ||| NN
success  ||| S:1060 E:1068 ||| NN
may  ||| S:1068 E:1072 ||| MD
be  ||| S:1072 E:1075 ||| VB
warranted  ||| S:1075 E:1085 ||| VBN
as  ||| S:1085 E:1088 ||| IN
more  ||| S:1088 E:1093 ||| JJR
data  ||| S:1093 E:1098 ||| NNS
become  ||| S:1098 E:1105 ||| VBP
available ||| S:1105 E:1114 ||| JJ
.  ||| S:1114 E:1116 ||| .
